AstraZeneca's (AZ) patent for levothyroxine (LT4) is set to expire in the US on April 8, 2024. The patent is expected to expire in the near future, with generic manufacturers AstraZeneca (AZ) and Ranbaxy Laboratories (RBS) are expected to launch their generic levothyroxine tablets at the same time.
The patent for LT4 is expected to be expiring in April 2024, with generic manufacturers AstraZeneca (AZ) and Ranbaxy Laboratories (RBS) being expected to launch their generic levothyroxine tablets at the same time.
“Our patent for LT4, a generic version of Synthroid (levothyroxine) is due to expire in the US in April 2024,” said an AstraZeneca spokesperson. “AstraZeneca is confident that they will launch a generic version of Synthroid and make the generic version available in the US in the near future.”
AstraZeneca is the only company that has a patent on levothyroxine (LT4) in the US. In 2016, the patent for the medication expired in the US in the same period, with Ranbaxy and AstraZeneca now supplying the medication. Ranbaxy is now supplying an alternative brand name version of the medication, Synthroid, in the US.
The patent for Synthroid is set to expire in the US on April 8, 2024, with generic manufacturers AstraZeneca (AZ) and Ranbaxy Laboratories (RBS) now supplying Synthroid in the US.
Photograph: Reuters/iStock / Felix SalmonAstraZeneca (AZ) is one of the world’s largest drug companies with a combined revenue of $3.7 billion in the US in 2019. Its most profitable drugs are used to treat obesity and diabetes. The company’s products are used for treating cardiovascular, renal, and gastrointestinal disorders.
AstraZeneca is the only company with a patent on levothyroxine (LT4) and it is also the only company to have a patent on Synthroid, which is available from its manufacturer. Ranbaxy, which produces the medicine, is the only company that has a patent on the drug.
“As of today, Synthroid (Levothyroxine) is the only treatment approved by the US Food and Drug Administration (FDA) to treat hypothyroidism, a condition that causes a failure in the production of the thyroid hormone which is essential for building the body’s energy, metabolism and body’s overall metabolic function,” said Daniel J. Kline, Chairman and CEO of AZ.
“We are confident that these generic drugs will be launched in the US,” he continued. “We will be introducing an alternative to Synthroid and we will continue to make a commitment to our shareholders to support our shareholders in our pursuit of a future in which the companies that make our medicines have a healthy, balanced and successful business.”
AstraZeneca is the only company to have a patent on Synthroid, which is available from its manufacturer.
AstraZeneca is the only company to have a patent on levothyroxine (LT4) and it is also the only company to have a patent on a generic version of the medication, Synthroid. Ranbaxy, which is the manufacturer of the medication, is the only company to have a patent on a generic version of the medication.
Kline, Chairman and CEO.
AstraZeneca is the only company with a patent on levothyroxine (LT4) and it is also the only company to have a patent on a generic version of the medication, Synthroid.
Synthroid is a brand-name medication that contains the generic form of levothyroxine. It is primarily used to treat hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormones. This medication works by replacing the amount of thyroid hormone the body needs, which is why it is sometimes prescribed for uses that are not listed in thehormone chart.
In addition to its use in treating hypothyroidism, Synthroid may also be used for purposes not listed in the hormone chart. Synthroid should not be taken by individuals under 18 or over 65. Additionally, Synthroid may also be used for purposes other than listed in the hormone chart.
The dosage of Synthroid may vary depending on the individual and the underlying cause of hypothyroidism. It is important to follow the prescribed dosage and instructions provided by your healthcare provider. Synthroid should not be taken by individuals with a history of thyroid cancer, blood clots, liver disease, or kidney disease.
It is also important to note that Synthroid does not work if the person is not taking an antacid (e.g., citric acid anhydrous, sodium citrate, or citric acid monohydrate). In that case, your doctor may adjust the antacid based on the symptoms and signs.
It is important to discuss Synthroid with your healthcare provider before starting or stopping treatment with this medication. Abrupt discontinuation of treatment with levothyroxine can lead to symptoms such as hypothyroidism and even death. If you have had sudden discontinuation of treatment with levothyroxine, contact your healthcare provider immediately.
If you are in the United States, Canada, or Australia, you can also order generic levothyroxine tablets through our website or call 1-800-467-5146 before they reach our pharmacy. We will issue a policy on each generic.
Read More About SynthroidSynthroid is a brand-name medication that contains the generic form of levothyroxine. It is primarily used to treat hypothyroidism in adults and children. It is prescribed to individuals with a thyroid hormone deficiency because the amount of thyroid hormone that is produced is insufficient. When used to treat hypothyroidism in adults, Synthroid replaces the amount of thyroid hormone the body needs. It works by replacing the amount of thyroid hormone the body needs, which is why it is sometimes prescribed for uses not listed in the hormone chart.
Synthroid should be taken by individuals with a history of thyroid cancer, blood clots, liver disease, or kidney disease.
Additionally, Synthroid should not be used by individuals who have a history of hypothyroidism or are over 65 years of age. It should not be used by individuals who are pregnant or breastfeeding without consulting your healthcare provider.
It is important to note that Synthroid does not work if you are taking an antacid (e.g., citric acid anhydrous, sodium citrate, or citric acid monohydrate).
It is important to note that Synthroid should not be taken by individuals with a history of thyroid cancer, blood clots, liver disease, or kidney disease. It should only be used by individuals with a history of thyroid cancer, blood clots, liver disease, or kidney disease.
The most important thing to remember when buying levothyroxineonline:You must be cautious about buying online without a prescription, as you may not be able to afford this medication. The best way to buy levothyroxine online is through a prescription.
When buying levothyroxine online, be sure to look for the ‘brand name’ or the ‘manufacturer’ of the medication. This will allow you to find the medication you need online without leaving your home. The best way to get this medication is through a prescription. However, if you have doubts about buying levothyroxine online, ask your doctor or pharmacist for a prescription.
Levothyroxine is an oral prescription medication. It is used to treat hypothyroidism and certain thyroid disorders, including Hashimoto’s thyroiditis and thyroid cancer. It is also prescribed for patients who have a history of hyperthyroidism.
Levothyroxine is a synthetic thyroid hormone, which works by replacing the amount of thyroid hormone in the body. It is used to treat thyroid gland symptoms and disorders, including Hashimoto’s thyroiditis, Hashimoto's thyroiditis, and thyroid cancer. Levothyroxine is a synthetic form of the thyroid hormone T4, which is found in the body.
Levothyroxine is available as an oral tablet and an oral capsule. It is usually taken once a day, and your doctor will prescribe it if you want to take it for a full treatment period.
Levothyroxine is a synthetic thyroid hormone that is taken by the body. It replaces the amount of thyroid hormone in the body, which is a hormone that is produced by the thyroid gland. Levothyroxine is usually taken in the morning before eating a meal or taking a snack.
Take levothyroxine on an empty stomach or as directed by your doctor. It can be taken with or without food.
Levothyroxine is a synthetic thyroid hormone that works by replacing the amount of thyroid hormone in the body. It is a synthetic hormone that is produced by the thyroid gland. Levothyroxine is used to treat hypothyroidism, an enlarged thyroid gland, or Hashimoto's thyroiditis, a thyroid condition in which the thyroid gland cannot produce enough thyroid hormone.
Levothyroxine is a synthetic thyroid hormone that is taken by the body to treat hypothyroidism. It is a synthetic hormone that is produced by the thyroid gland and is used to treat thyroid gland problems such as Hashimoto's thyroiditis, hypothyroidism, or thyroid cancer. It can be taken once a day, and your doctor will prescribe it for a full treatment period.
Like all medications, Levothyroxine can cause side effects. These can include weight gain, dry mouth, headache, upset stomach, constipation, loss of appetite, nausea, vomiting, and fatigue.
However, it is important to note that side effects of Levothyroxine are rare and tend to be mild and temporary. It is not recommended to take Levothyroxine if you are pregnant, planning to have a baby, or breastfeeding.
Levothyroxine (T4) and aspartate aminotransferase (ALT) level, and specific metabolic pathway were used to assess the metabolic profile in patients with various autoimmune thyroid conditions. In the present study, we investigated the metabolic profile in patients with various autoimmune thyroid conditions including Hashimoto thyroiditis, Graves’ disease, and autoimmune myositis, and evaluated the specific metabolic pathway in patients with Hashimoto’s thyroiditis. Synthroid and levothyroxine were orally administered to all patients. Serum TSH, ACTH, and AMT were measured by radioimmunoassay. Serum levels of ALT and AST were significantly elevated in patients with Hashimoto thyroiditis compared to controls. Moreover, the specific metabolic pathway in patients with Hashimoto’s thyroiditis was examined, and the relationship between the specific metabolic pathway and the clinical manifestations was analyzed. In conclusion, our study found that both the specific metabolic pathway and the metabolic pathway in patients with Hashimoto’s thyroiditis were significantly elevated. Moreover, the specific metabolic pathway and the metabolic pathway in patients with Graves’ disease were significantly elevated. However, the specific metabolic pathway in patients with Hashimoto’s thyroiditis was significantly elevated. These findings suggested that the specific metabolic pathway was elevated in patients with Hashimoto’s thyroiditis.
This study was a single center observational cohort study between 2011 and 2019 conducted by the Research Ethics Committee at Shandong Medical University from which no ethics committee was involved. The Institutional Review Board of Shandong Medical University approved the study protocol and protocol of this study.
Between 2011 and 2019, we recruited patients with Hashimoto’s thyroiditis (ATI) who were diagnosed with Hashimoto’s thyroiditis. According to the criteria, patients with Hashimoto’s thyroiditis were classified into 2 subgroups: Hashimoto’s thyroiditis subgroups A and B. In subgroup A, we enrolled patients with Hashimoto’s thyroiditis, and those in subgroup B were diagnosed with Hashimoto’s thyroiditis. The details of all patients with ATI were collected and recorded in the form of medical record and medical data. According to the criteria, patients with Hashimoto’s thyroiditis were divided into 2 subgroups: subgroup C was diagnosed with Hashimoto’s thyroiditis, and subgroup D was diagnosed with Hashimoto’s thyroiditis.
According to the criteria of the current study, we enrolled patients with Hashimoto’s thyroiditis and those in subgroup D. We enrolled patients with Hashimoto’s thyroiditis in subgroup D. The details of all patients with Hashimoto’s thyroiditis were collected and recorded in the form of medical record and medical data.
We conducted a single center observational cohort study between 2011 and 2019, using a retrospective analysis. The patients with Hashimoto’s thyroiditis were enrolled into two subgroups: subgroup C was diagnosed with Hashimoto’s thyroiditis, and subgroup D was diagnosed with Hashimoto’s thyroiditis. The study population consisted of 1099 patients with Hashimoto’s thyroiditis who were diagnosed with Hashimoto’s thyroiditis.
The primary objective of this study was to explore the metabolic pathway in patients with Hashimoto’s thyroiditis. The research ethics committee of Shandong Medical University approved the study protocol. Patients with Hashimoto’s thyroiditis were enrolled into 2 subgroups: subgroup C was diagnosed with Hashimoto’s thyroiditis, and subgroup D was diagnosed with Hashimoto’s thyroiditis.
Salt Composition in both
Salt Composition
Thyroid anticonvulsant hormone Cetostearyl alcohol propionyl alcohol propionyl alcohol 22.5mg(same for both)
You Searched
Strip of 10 tablets
We only sell the best substitute from top brands
Our Recommendation
Levothyroxine Synthroid 112mg Tablet 10s
1,979+ Customers trust this
WHO GMP Certified
Marketed by
Levothyroxine Synthroid 112 mg Tablet 10s
Doctor ApprovedMedicine Comparison
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
Stade de France Pharmacy